Intrinsic and acquired resistance to methotrexate in acute leukemia

New England Journal of Medicine

Volumn 335, Issue 14, 1996, Pages 1041-1048

  Gorlick, Richard ^a   Goker, Erdem ^a   Trippett, Tanya ^a   Waltham, Mark ^a   Banerjee, Debabrata ^a   Bertino, Joseph R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; DIHYDROFOLATE REDUCTASE; EDATREXATE; FOLIC ACID ANTAGONIST; FOLINIC ACID; LOMETREXOL; METHOTREXATE; METHOTREXATE DERIVATIVE; N2 (4 AMINO 4 DEOXY 10 METHYLPTEROYL) N6 (4' FLUORESCEINTHIOCARBAMOYL)LYSINE; PEMETREXED; RALTITREXED; RETINOBLASTOMA PROTEIN; TRIMETREXATE; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; BLAST CELL; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG RESISTANCE; DRUG TRANSPORT; HUMAN; PRIORITY JOURNAL; REVIEW;

ACUTE DISEASE; DRUG RESISTANCE; GENES, TUMOR SUPPRESSOR; HUMANS; LEUKEMIA; METHOTREXATE;

EID: 0029846176     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199610033351408     Document Type: Review

References (59)

1. Jolivet J, Cowan KH, Cure GA, Clendeninn NJ, Chabner BA. The pharmacology and clinical use of methotrexate. N Engl J Med 1983;309:1094-104.
2. Hausknecht RU. Methotrexate and misoprostol to terminate early pregnancy. N Engl J Med 1995;333:537-40.
3. Hitchings GH Jr. Selective inhibitors of dihydrofolate reductase. In Vitro Cell Dev Biol 1989;25:303-10.
4. Allegra CJ, Chabner BA, Tuazon CU, et al. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 1987;317:978-85.
5. Pui C-H. Childhood leukemias. N Engl J Med 1995;332: 1618-30.
6. Jonsson OG, Kamen BA. Methotrexate and childhood leukemia. Cancer Invest 1991;9:53-60.
7. Bertino JR. Ode to methotrexate. J Clin Oncol 1993;11:5-14.
8. Bertino JR, Romanini A. Folate antagonists. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer medicine. Vol. 1. 3rd ed. Philadelphia: Lea & Febiger, 1993:698-711.
9. Chu E, Allegra CJ. Antifolates. In: Chabner BA, Longo DL, eds. Cancer chemotherapy and biotherapy: principles and practice. Philadelphia: Lippincott-Raven, 1996:109-48.
10. Li WW, Fan JY, Hochhauser D, et al. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci USA 1995;92:10436-40.
11. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78:539-42.
12. Spinella MJ, Brigle KE, Sierra EE, Goldman ID. Distinguishing between folate receptor alpha-mediated transport and reduced folate carrier-me diated transport in L1210 leukemia cells. J Biol Chem 1995;270: 7842-9.
13. Westerhof GR, Rijnboutt S, Schornagel JH, Pinedo HM, Peters GJ, Jansen G. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-1 cells expressing folate-binding protein. Cancer Res 1995;55: 3795-802.
14. McGuire JJ, Coward JK. Pteroylpolyglutamates: biosynthesis, degradation, and function. In: Blakley RL, Benkovic SJ, eds. Folates and pterins. Vol. 1. Chemistry and biochemistry of folates. New York: John Wiley, 1984:135-90.
15. Chabner BA, Allegra CJ, Curt GA, et al. Polyglutamation of methotrexate: is methotrexate a prodrug? J Clin Invest 1985;76:907-12.
16. Barrueco JR, O'Leary DE, Sirotnak FM. Metabolic turnover of methotrexate polyglutamates in lysosomes derived from S180 cells: definition of a two-step process limited by medial lysosomal permeation of poly glutamates and activating reduced sulfhydryl compounds. J Biol Chem 1992;267:15356-61.
17. Schimke RT. Gene amplification in cultured cells. J Biol Chem 1988; 263:5989-92.
18. Stark GR, Debatisse M, Giulotto E, Wahl GM. Recent progress in understanding mechanisms of mammalian DNA amplification. Cell 1989;57: 901-8.
19. Williams FM, Flintoff WF. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake. J Biol Chem 1995;270:2987-92.
20. Moscow JA, Gong M, He R, et al. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res 1995;55:3790-4.
21. Wong SC, Proefke SA, Bhushan A, Matherly LH. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. J Biol Chem 1995;270:17468-75.
22. Schweitzer BI, Dicker AP, Bertino JR. Dihydrofolate reductase as a therapeutic target. FASEB J 1990;4:2441-52.
23. Melera PW. Acquired versus intrinsic resistance to methotrexate: diversity of the drug-resistant phenotype in mammalian cells. Semin Cancer Biol 1991;2:245-55.
24. Dicker AP, Waltham MC, Volkenandt M, et al. Methotrexate resistance in an in vivo mouse tumor due to a non-active-site dihydrofolate reductase mutation. Proc Natl Acad Sci USA 1993;90:11797-801.
25. Pizzorno G, Mini E, Coronnello M, et al. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug. Cancer Res 1988;48: 2149-55.
26. Li WW, Waltham M, Tong W, Schweitzer BI, Bertino JR. Increased activity of γ-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate. In: Ayling JE, Nair MG, Baugh CM, eds. Chemistry and biology of pteridines and folates. Vol. 338 of Advances in experimental medicine and biology. New York: Plenum Press, 1993:635-8.
27. Rhce MS, Wang Y, Nair GM, Galivan J. Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity. Cancer Res 1993;53:Suppl:2227-30.
28. Hyde JE. The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites. Pharmacol Ther 1990;48:45-59.
29. Trippett T, Schlemmer S, Elisseyeff Y, et al. Detective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia. Blood 1992;80:1158-62.
30. Klohs WD, Steinkampf RW, Besserer JA, Fry DW. Cross resistance of pleiotropically drug resistant P338 leukemia cells to the lipophilic anti-folates trimetrexate and BW 301U. Cancer Lett 1986;31:253-60.
31. Gorlick R, Goker E, Trippett T, Eliseyeff Y, Flintoff W, Bertino JR. Decreased reduced folate carrier expression is observed in human leukemic blasts with defective methotrexate transport. Proc Am Assoc Cancer Res 1996;37:317. abstract.
32. Goker E, Waltham M, Kheradpour A, et al. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood 1995;86:677-84.
33. Matherly LH, Taub JW, Ravindranath Y, et al. Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood 1995;85:500-9.
34. Lin JT, Tong WP, Trippett TM, et al. Basis for natural resistance to methotrexate in human acute non-lymphocytic leukemia. Leuk Res 1991; 15:1191-6.
35. Hryniuk WM, Bertino JR. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. J Clin Invest 1969;48:2140-55.
36. Rodenhuis S, McGuire JJ, Narayanan R, Bertino JR. Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells. Cancer Res 1986;46:6513-9.
37. Whitehead VM, Rosenblatt DS, Vuchich MJ, Shuster JJ, Witte A, Beaulieu D. Accumulation of methotrexate and methotrexate poly-glutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. Blood 1990;76:44-9.
38. Goker E, Lin JT, Trippett T, et al. Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. Leukemia 1993;7:1000-4.
39. Barredo JC, Synold TW, Laver J, et al. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 1994;84:564-9.
40. Synold TW, Relling MV, Boyett JM, et al. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 1994;94:1996-2001.
41. Goker E, Kheradpour A, Waltham M, et al. Acute monocytic leukemia: a mycloid leukemia subset that may be sensitive to methotrexate. Leukemia 1995;9:274-6.
42. Ncvins JR. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992;258:424-9.
43. Ahuja HG, Jat PS, Foti A, Bar-Eli M, Cline MJ. Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. Blood 1991; 78:3259-68.
44. Kornblau SM, Xu HJ, Zhang W, et al. Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. Blood 1994; 84:256-61.
45. Hochhauser D, Schnieders B, Ercikan-Abali E, et al. Cyclin D1 over-expression increases DHFR expression and confers resistance to methotrexate. J Natl Cancer Inst (in press).
46. dc Boer CJ, Schuuring E, Dreef E, et al. Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood 1995;86:2715-23.
47. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992;70:923-35.
48. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992;70:937-48.
49. Jackman AL, Calvert AH. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 1995;6:871-81.
50. Sirotnak FM, DeGraw JI, Schmid FA, et al. New folate analogs of the 10-deazaaminopterin series: further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid tumor models. Cancer Chemother Pharmacol 1984;12:26-30.
51. Jackman AL, Gibson W, Brown M. The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. Adv Exp Med Biol 1993;339:265-76.
52. Zalcberg JR, Cunningham D, Van Cutsem E, et al. ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 1996;14:716-21.
53. Mauritz R, Bekkenk M, Pieters R, Veerman AJP, Peters GJ, Jansen G. Resistance to methotrexate and sensitivity for novel antifolates in different types of childhood leukemia. Blood 1994:84:Suppl 1:45a. abstract.
54. Kamen BA, Eibl B, Cashmore A, Bertino J. Uptake and efficacy of trimetrexate (TMQ,2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cells in vitro. Biochem Pharmacol 1984;33:1697-9.
55. Fry DW, Besserer JA. Characterization of trimetrexate transport in human lymphoblastoid cells and development of impaired influx as a mechanism of resistance to lipophilic antifolates. Cancer Res 1988;48: 6986-91.
56. Lin JT, Bertino JR. Update on trimetrexate, a folate antagonist with antincoplastic and antiprotozoal properties. Cancer Invest 1991;9: 159-72.
57. Pappo A, Dubowy R, Ravindranath Y, et al. Phase II trial of trimetrexate in the treatment of recurrent childhood acute lymphoblasric leukemia: a Pediatric Oncology Group study. J Natl Cancer Inst 1990;82: 1641-2.
58. Kheradpour A, Berman E, Goker E, Lin JT, Tong WP, Bertino JR. A phase II study of continuous infusion of trimetrexate in patients with refractory acute leukemia. Cancer Invest 1995;13:36-40.
59. Lacerda JF, Goker E, Kheradpour A, et al. Selective treatment of SCID mice bearing methotrexate-transport-resistant human acute lymphoblastic leukemia tumors with trimetrexate and leucovorin protection. Blood 1995; 85:2675-9.